Among top 10 most promising drugs
TSX Exchange Symbol: RVX
CALGARY, July 9 /CNW/ - Resverlogix Corp's ("Resverlogix" or the
"Company") (TSX:RVX) novel lead ApoA-I drug candidate, RVX-208 has been
selected as one of the top 10 most promising cardiovascular disease (CVD)
drugs available for strategic partnering by an independent committee assembled
by Windhover Information, a leading provider of business information products
and services to senior executives in the pharmaceutical, biotechnology, and
medical device industries.
"We are honored to be part of this select group of top ten most promising
innovative drugs," stated Donald McCaffrey, President and CEO of Resverlogix.
"It again validates RVX-208 and our entire NexVas(TM) PR franchise as an
important new small molecule drug for the largest market with unmet needs,
atherosclerosis and cardiovascular diseases. We are moving towards our next
important milestone, Phase 1b/2a, later this fall and continue to measure
safety, tolerability and key reverse cholesterol transport (RCT) markers such
as ApoA-I, pre-beta HDL, HDL and cholesterol efflux."
The selection committee was led by Marc Wortman, PhD, contributing writer
to Windhover's IN VIVO and Start Up publications, and Michael Rice, Senior
Consultant, and Ed Saltzman, President of Defined Health, a leading business
development strategy consulting firm. Drawing on the analytic resources of
these organizations, the group evaluated hundreds of compounds currently in
development for the treatment of cardiovascular disease prior to selecting
RVX-208 among the top ten most attractive drug available for partnering.
"Selected companies have been screened using a strict set of judging
criteria for the Top 10 award, and represent what our committee considered the
most attractive cardiovascular opportunities the industry has to offer,"
stated Roger Longman, Managing Director of Windhover Information. "Winners
have met strict criteria including: unmet medical need, market potential,
diversity of indications, strong science, multi-level partnering opportunities
(biotech and pharma), potential for new opportunities beyond initial
indications, history of the molecule and drug and be a strong company."
"To have a highly regarded selection committee realize the commercial
potential for RVX-208 is important for us," stated Kenneth Lebioda, Senior
Vice President of Business and Corporate Development at Resverlogix.
"Atherosclerosis, the leading underlying cause of cardiovascular death,
represents the largest cost center to health systems globally. Novel small
molecules that enhance ApoA-I production have a diverse number of patient
groups that they can help such as low HDL, acute coronary syndrome, diabetes,
post myocardial infarction and Alzheimer's. A novel drug that could help these
diseases will have a major positive impact on patients and health systems
alike. This is where RVX-208 offers an unrivalled commercial opportunity for
the life science industry," added Mr. Lebioda.
As a selected company, Resverlogix has been invited to present data on
RVX-208 at Windhover's Therapeutic Area Partnerships conference on
November 3-5, 2008 in Philadelphia.
Windhover Information Inc., an Elsevier company, has led the field in
providing analysis of the healthcare industry to decision-makers at all levels
since the founding of its flagship publication, IN VIVO, The Business &
Medicine Report, in 1983. Windhover provides its information and analysis in
many formats, including print, electronic databases, international conferences
and webinars. For more on the company's products and services, please see
About Resverlogix Corp.
Resverlogix Corp. is a leading biotechnology company engaged in the
development of novel therapies for important global medical markets with
significant unmet needs. The NexVas(TM) program is the Company's primary focus
which is to develop novel small molecules that enhance ApoA-I. These vital
therapies address the grievous burden of atherosclerosis and other important
diseases such as acute coronary syndrome, diabetes, Alzheimer's and other
vascular disorders. The Company's secondary focus is TGF-Beta Shield(TM), a
program that aims to address burgeoning grievous diseases, such as cancer and
fibrosis. Resverlogix Corp. trades on the Toronto Stock Exchange (TSX:RVX).
For further information please visit www.resverlogix.com.
This news release may contain certain forward-looking statements that
reflect the current views and/or expectations of Resverlogix Corp. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly. The TSX Exchange does not accept
responsibility for the adequacy or accuracy of this news release.
For further information:
For further information: Theresa Kennedy, VP, Corporate Communications,
Resverlogix Corp., Phone: (604) 538-7072, Fax: (403) 256-8495, Email:
Theresa@resverlogix.com; Sarah Zapotichny, Manager, Investor Relations,
Resverlogix Corp., Phone: (403) 254-9252, Fax: (403) 256-8495, Email:
Sarah@resverlogix.com, Website: www.resverlogix.com